BioInvent International AB
11 clinical trials · Sponsor
◉ Watch BioInvent International AB
| Record | Firm | Date |
|---|---|---|
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma (NCT06784648) | BioInvent International AB | 2024-12-11 |
| BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors (NCT06205706) | BioInvent International AB | 2023-12-04 |
| BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors (NCT05555251) | BioInvent International AB | 2022-07-28 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (NCT04752826) | BioInvent International AB | 2021-01-25 |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04219254) | BioInvent International AB | 2020-06-29 |
| A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL (NCT03571568) | BioInvent International AB | 2018-05-16 |
Track BioInvent International AB automatically
Every clearance here is in the API, with alerts when new ones post.